Germline mutations in POLE and POLD1 are linked to variable cancer risks, with findings highlighting mutation-specific differences that refine tumor predisposition assessment.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The challenge of identifying unknowns looms large for mass spectrometry, says Susan Richardson, who returned from ASMS 2025 with new ideas – and a hope that AI might finally bridge the gap between data and discovery